MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
131.62
+6.45
+5.15%
After Hours: 131.62 0 0.00% 17:12 07/02 EDT
OPEN
125.89
PREV CLOSE
125.17
HIGH
131.87
LOW
125.24
VOLUME
708.39K
TURNOVER
--
52 WEEK HIGH
131.87
52 WEEK LOW
49.38
MARKET CAP
8.46B
P/E (TTM)
-72.9682
1D
5D
1M
3M
1Y
5Y
1D
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock
Barchart · 2d ago
Protagonist Therapeutics grants inducement awards for 8,650 share options, 2,275 RSUs to new hires
PUBT · 3d ago
Protagonist Therapeutics Reports Granting of Inducement Awards
Barchart · 3d ago
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
Seeking Alpha · 5d ago
Weekly Report: what happened at PTGX last week (0622-0626)?
Weekly Report · 5d ago
Insider Cashes In: Major Protagonist Therapeutics Stock Sale Shakes Up Investors
TipRanks · 06/26 02:01
Protagonist Therapeutics director William D. Waddill disposes of common shares worth $1.06 million
PUBT · 06/25 20:11
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Benzinga · 06/24 18:22
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.